Revance Therapeutics, Inc. (RVNC)
| Market Cap | 2.01B |
| Revenue (ttm) | 15.33M |
| Net Income (ttm) | -282.09M |
| Shares Out | 58.01M |
| EPS (ttm) | -4.86 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 10 |
| Last Price | $27.43 |
| Previous Close | $28.48 |
| Change ($) | -1.05 |
| Change (%) | -3.69% |
| Day's Open | 28.14 |
| Day's Range | 27.43 - 28.56 |
| Day's Volume | 305,750 |
| 52-Week Range | 18.39 - 34.62 |
Shares of Revance Therapeutics (NASDAQ:RVNC) were flat in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share increased 6.09% over the past year to ($1.08), ...
NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance Reports First Quarter 2021 Financial Results, Provides Corporate Update
NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance to Release First Quarter 2021 Financial Results on Monday, May 10, 2021
Revance Therapeutics, Inc. (RVNC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance to Share Data at The Aesthetic Meeting 2021 that Supports DaxibotulinumtoxinA's 24-Week Duration Profile Across Multiple Female Age Cohorts
NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance Announces First Patient Enrolled for DaxibotulinumtoxinA in Glabellar Lines and Cervical Dystonia in China by Fosun Pharma
NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance to Participate in the 20th Annual Needham Virtual Healthcare Conference
NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance to Showcase Phase 3 Results Evaluating DaxibotulinumtoxinA for Injection for the Treatment of Cervical Dystonia at AAN Annual 2021 Meeting
Revance Therapeutics, Inc. (RVNC) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the n...
NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance to Participate in Upcoming Virtual Healthcare Conferences
Dublin, Feb. 24, 2021 (GLOBE NEWSWIRE) -- The "Facial Injectable Market - Forecasts from 2020 to 2025" report has been added to ResearchAndMarkets.com's offering. The facial injectable market is project...
NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO--(BUSINESS WIRE)--Ambrx Appoints Audit Executive Chris Nolet to Board of Directors
Revance Therapeutics Inc (NASDAQ: RVNC) has reported topline data from JUNIPER Phase 2 study evaluating DaxibotulinumtoxinA for Injection to treat adults with moderate to severe upper limb spasticity. I...
Shares of Revance Therapeutics (NASDAQ:RVNC) increased in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share fell 25.25% year over year to ($1.24), which we...
NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance Announces Positive Topline Phase 2 Data Supporting Advancement of DaxibotulinumtoxinA for Injection for the Treatment of ULS
NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance Reports Fourth Quarter and Full Year 2020 Financial Results
NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance Appoints Olivia C. Ware and Carey O'Connor Kolaja to Board of Directors
On Monday, February 22, Revance Therapeutics (NASDAQ:RVNC) will release its latest earnings report. Benzinga's outlook for Revance Therapeutics is included in the following report.
NASHVILLE, Tenn.--(BUSINESS WIRE)--Governor Lee, Commissioner Rolfe Announce Revance Therapeutics to Relocate Global Headquarters to Nashville
Revance (RVNC) announces a delay in the FDA decision on its BLA for DaxibotulinumtoxinA for Injection due to COVID-19.
Revance Therapeutics, Inc. (RVNC) CEO Mark Foley on Q3 2020 Results - Earnings Call Transcript
Shares of Revance Therapeutics (NASDAQ:RVNC) decreased 8.62% in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share were down 39.58% year over year to ($1.34...
Revance (RVNC) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Revance Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating. The post Stocks Showing Market Leadership: Revance Therapeutics Earns 93 RS Rating appeare...
Revance Therapeutics, Inc. (RVNC) CEO Mark Foley on Q2 2020 Results - Earnings Call Transcript
Revance Therapeutics (RVNC) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
Revance Therapeutics, Inc. (RVNC) CEO Mark Foley on Q1 2020 Results - Earnings Call Transcript
As of late, it has definitely been a great time to be an investor in Revance Therapeutics.
Revance (RVNC) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Investors need to pay close attention to Revance Therapeutics (RVNC) stock based on the movements in the options market lately.
Revance Therapeutics, Inc. (RVNC) CEO Mark Foley on Q4 2019 Results - Earnings Call Transcript
The company's frown line treatment moved closer to commercialization today.
As of late, it has definitely been a great time to be an investor in Revance Therapeutics.
Revance Therapeutics: A Robust Pick For 2020
A new deal accelerates the company's shift to a commercial-stage biotech.
Revance Therapeutics: The Real Threat To Abbvie's Dividend
Several companies raised capital on Wednesday.
The pricing of a secondary offering is to blame.
Revance Therapeutics, Inc. (RVNC) CEO Mark Foley on Q3 2019 Results - Earnings Call Transcript
Earlier this month, Revance Therapeutics Inc (NASDAQ: RVNC) named Mark Foley as its new CEO.
Possible merger and acquisition activity lifted one of these stocks.
Biotech Revance Therapeutics Inc. RVNC, +4.46% said Monday it has named Mark J. Foley as chief executive, replacing Dan Browne who has stepped down due to a misjudgment in handling an employee matter.
Revance's DAXI seems to have a longer duration of effect than botox and its current competitors.
Revance Therapeutics, Inc. (RVNC) CEO Daniel Browne on Q2 2019 Results - Earnings Call Transcript
Revance (RVNC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Revance's share price has been battered over the past year.
Revance Therapeutics (RVNC) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
Revance Therapeutics, Inc. (RVNC) on Q1 2019 Results - Earnings Call Transcript
About RVNC
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection (DAXI), which has completed phase III clinical trials for the treatment of glabellar (frown) lines and cervical dystonia; is in phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe late... [Read more...]
| Industry Biotechnology | IPO Date Feb 6, 2014 |
| CEO Mark Foley | Employees 470 |
| Stock Exchange NASDAQ | Ticker Symbol RVNC |
Financial Performance
In 2020, RVNC's revenue was $15.33 million, an increase of 3,610.65% compared to the previous year's $413,000. Losses were -$282.09 million, 76.9% more than in 2019.
Analyst Forecasts
According to 11 analysts, the average rating for RVNC stock is "Buy." The 12-month stock price forecast is 38.20, which is an increase of 39.26% from the latest price.